Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| INDS | Registry Identifier | MR1811190620 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
During COVID-19 epidemic, hydroxychloroquine was proposed and authorized as a possible key agent in the treatment of COVID-19 hospitalized pneumonia, including in France. Gautret et al. proposed the combination regimen with azithromycin. However only one study reported the interest of azithromycin alone.
Retrospective study reporting the impact of the anti-infective agents used during the pandemic in a tertiary care hospital, using azithromycin with or without hydroxychloroquine.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Azithromycin or non-azithromycin group | Patient who received during admission for a severe COVID-19 pneumonia, azithromycin +/-hydroxychloroquine or no azithromycin. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| favorable outcome | Drug | Whether patient under such regimen had a favorable outcome (no transfer in intensive care unit or death) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Favorable outcome | After being admitted, patient was monitored whether he does not required to be transferred in ICU or died because of a severe COVID-19 pneumonia within 7 days. The outcome was purely clinical. If patient was discharged at home after admission and/or was transferred into a rehabilitation center he was considered as a favorable outcome independently of any biological marker. | Assessed within 7 days after admission |
| Measure | Description | Time Frame |
|---|---|---|
| Risk factors 1 | Studying if biological abnormalities (lymphocyte count or CRP) at admission were associated with an unfavorable outcome | Assessed at day 1 |
| Risk factors 2 | Studying if comorbidities were associated with an unfavorable outcome |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
All patients admitted at Hopital Raymond Poincaré, Garches, France in a medical ward for a COVID-19 pneumonia
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Benjamin Davido | Garches | 92380 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D000086382 | COVID-19 |
| D011014 | Pneumonia |
| ID | Term |
|---|---|
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
| D014777 | Virus Diseases |
| D008171 | Lung Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| Assessed at day 1 |
| Interest of anti-infective agents | Studying whether any regimen was associated with a favorable outcome (including azithromycin) | From date of inclusion until the date of first documented progression to ICU or date of death from any cause, whichever came first, assessed up to 2 months |
| D012140 |
| Respiratory Tract Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |